Agilent Technologies Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On October 23, 2025, Agilent Technologies, Inc. (the "Company") appointed Adam S. Elinoff as Senior Vice President and Chief Financial Officer ("CFO") and principal financial officer of the Company effective November 17, 2025 (the "Start Date"), replacing Rodney Gonsalves, who has served as the Company's Interim CFO and Interim Principal Financial Officer since July 31, 2025. Mr. Gonsalves will continue to serve as the Company's Vice President, Corporate Controller and Principal Accounting Officer. Mr. Elinoff, age 48, has served as Vice President, Investor Relations and Treasurer of Amgen Inc. ("Amgen"), a global biotechnology company, since July 2025. Mr. Elinoff joined Amgen in 2006 and has held a series of finance, strategy, and transformation roles of increasing responsibility. From 2023 to July 2025, Mr. Elinoff served as Vice President, Finance and Treasurer. From 2020 to 2023, he served as Regional Chief Financial Officer for Europe, Middle East, Africa, Latin America, and Canada. From 2017 to 2020, he served as Executive Director and Head of Corporate Financial Planning and Analysis. Mr. Elinoff holds a Master of Business Administration from the W. P. Carey School of Business at Arizona State University and a Bachelor of Arts degree in Economics from Hamilton College. There are no arrangements or understandings between Mr. Elinoff and any other persons pursuant to which Mr. Elinoff was appointed Senior Vice President and CFO. Mr. Elinoff does not have any family relationship with any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Mr. Elinoff has no direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K. (e) In connection with Mr. Elinoff's employment, the Compensation Committee of the Company (the "Committee") approved the following compensation package: (i) effective as of the Start Date (a) a base salary of $700,000, and (b) eligibility to participate in the Company’s short-term annual incentive (bonus) program equal to 80% of his base salary; and (ii) effective as of November 18, 2025, a grant of (a) restricted stock units ("RSUs") of the Company’s common stock for fiscal 2025 in the target amount of $1,100,000 and (b) performance-based restricted stock units of the Company’s common stock for the fiscal 2026 to fiscal 2028 performance period in the target amount of $1,650,000 (collectively, the "FY 2026 Awards"). In addition, the Committee approved (i) a one-time cash bonus of $800,000, subject to repayment if Mr. Elinoff terminates his employment for any reason within twelve months, and (ii) a one-time sign-on grant of (a) RSUs of the Company's common stock in the target amount of $560,000, and (b) performance-based restricted stock units of the Company's common stock for the fiscal 2026 to fiscal 2028 performance period in the target amount of $840,000 (collectively, the "Sign-On Awards", and, together with the FY 2026 Awards, the "Awards"). The Awards are subject to the standard terms and conditions of the Company’s forms of equity award agreements under Agilent’s 2018 Stock Plan. The RSUs have a four-year vesting schedule. The performance-based restricted stock unit award will vest on October 31, 2028 with the actual payout ranging between 0% and 200% of the target based on the Company’s actual performance against performance goals established by the Committee for the three-year period ending on October 31, 2028. Mr. Elinoff will also enter into a change of control agreement with the Company in the form which is filed as Exhibit 10.37 to the Company’s Annual Report on Form 10-K filed with the SEC on December 22, 2014 and is incorporated by reference herein.